Dicot Pharma AB (publ) ("Dicot Pharma" or the "Company") recently announced the outcome of the exercise of its series TO 6 warrants. The exercise period for the TO 6 warrants ended on March 31, 2025, with an overall exercise rate of approximately 96 percent. As a result, Dicot Pharma receives approximately SEK 44 million before issue costs. The proceeds from the warrants will support preparations for the upcoming Phase 2b clinical trial, scaling of the supply chain, and advancing efforts to expand the product portfolio. The warrants were issued as part of the oversubscribed rights issue of units carried out in 2024, which raised approximately SEK 135 million, bringing the total proceeds to approximately SEK 179 million.

Dicot Pharma’s full press release is available here.

Background

Over the past year, Dicot Pharma has reached several milestones in the development of both the Company and its erectile dysfunction drug candidate, LIB-01. The Phase 1 clinical trial delivered strong results, and a Phase 2a study is currently underway. The Company has also secured a new US patent family, extending intellectual property protection until 2042. In parallel, new research findings in the field of metabolic diseases have been made, opening the possibility of addressing conditions such as obesity and diabetes.

Building on these advancements, Dicot Pharma is now preparing for the next stages of development. Key upcoming activities include finalising and reporting the results of the Phase 2a study, expected in mid-2025, while preparations for the subsequent Phase 2b trial are already in progress, with the trial anticipated to commence in 2026. To further strengthen its long-term market position, the Company is intensifying efforts around international expansion and future commercialisation. In addition, the evaluation and development of new indications to broaden the product portfolio remains an important focus area.

The proceeds from the warrants TO6 will be allocated as follows:
– Partial financing of the clinical phase 2b study, scaling of the supply chain, and other preparations to make the company phase 3-ready as soon as possible (approximately 80 percent).
– Evaluation and development to expand the product portfolio with new indications, including metabolic diseases (approximately 20 percent).

About Dicot Pharma AB

Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma's business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market.

Dicot Pharma is listed on Nasdaq First North and has approximately 9,100 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.

Corpura acted as financial advisor in connection with the exercise of the warrants.